<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preinvasive and invasive cervical neoplasia in patients with HIV infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preinvasive and invasive cervical neoplasia in patients with HIV infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preinvasive and invasive cervical neoplasia in patients with HIV infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William R Robinson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Aboulafia, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with HIV infection have higher rates of preinvasive (ie, cervical intraepithelial neoplasia [CIN]) and invasive cervical neoplasia compared with patients without HIV infection. In 1993, the Centers for Disease Control and Prevention (CDC) designated moderate and severe CIN as a condition of early symptomatic HIV infection and invasive cervical cancer as an AIDS-defining condition; since that time, cervical cancer has become one of the most common AIDS-related malignancies. Furthermore, patients with HIV and cervical cancer are at a higher risk for overall mortality than patients without HIV and cervical cancer.</p><p>Specific issues regarding preinvasive and invasive cervical neoplasia in patients with HIV infection are reviewed here. Screening for cervical cancer and the evaluation of abnormal screening results in patients with HIV infection, as well as other related issues, are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3220.html" rel="external">"Screening for cervical cancer in patients with HIV infection and other immunocompromised states"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3202.html" rel="external">"Screening for cervical cancer in resource-limited settings"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3216.html" rel="external">"Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>The incidence of histologically proven CIN is four to five times higher among patients with HIV infection compared with patients without HIV infection or adolescents with high-risk sexual behaviors [<a href="#rid1">1-3</a>]. In a prospective cohort study including over 650 patients with no evidence of CIN by Papanicolaou (Pap) test or colposcopy at study entry, patients with HIV (328 patients; mean CD4 count of 429 cells/microL) compared with patients without HIV (325 patients) were more likely to develop biopsy-confirmed CIN (20 versus 5 percent; incidence 8.3 versus 1.8 cases per 100 person-years) over the 30-month follow-up period [<a href="#rid3">3</a>]. Of the CIN lesions, almost 90 percent were low-grade lesions and no invasive cancers were noted.</p><p>Similarly, the risk of cervical cancer among patients with HIV is higher compared with patients without HIV [<a href="#rid4">4-9</a>]. In one retrospective study including over 62,000 patients with cervical cancer from 1996 to 2016, patients with HIV (609 patients) compared with patients without HIV had a higher incidence of squamous cell carcinoma (incidence ratio: 3.7, 95% CI 3.3-3.9) and adenocarcinoma (incidence ratio: 1.5, 95% CI 1-2.1) [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>As with patients without HIV, in patients with HIV, infection of the female genital tract with human papillomavirus (HPV) is generally felt to be necessary, but not sufficient, for the development of cervical cancer, as only a small percentage of patients infected with HPV develop cervical cancer. Major factors in pathogenesis, including viral subtype, older age, and duration of infection, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3216.html" rel="external">"Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention", section on 'Pathogenesis'</a>.)</p><p>In patients with HIV, immunosuppression is a key factor in pathogenesis, as a weakened response of the immune system allows persistence of the HPV infection. This is supported by the observation that patients with low CD4 cell counts (eg, CD4 count &lt;200 cells/microL):</p><p class="bulletIndent1"><span class="glyph">●</span>Have the highest prevalence of HPV infection [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More commonly harbor high-risk HPV types [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are at high risk for persistence of cervical HPV infection [<a href="#rid11">11-13</a>]. Some data suggest that HPV infection is likely to recur after a latent phase in patients with HIV, which is rarely seen in other patients [<a href="#rid14">14</a>].</p><p></p><p>The degree of immunosuppression in patients with HIV predicts both the occurrence and severity of cervical disease [<a href="#rid15">15-18</a>]. In a multicenter series of 485 patients with HIV, those with CD4 counts &lt;200 compared with &gt;500 cells/microL had a twofold increase in CIN and a lower rate of regression of untreated low-grade disease [<a href="#rid17">17</a>]. Subsequently, a case-control series of patients with HIV noted that those diagnosed with invasive cervical cancer had lower median CD4 counts and higher median HIV viral loads than those without cervical cancer [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H6383371"><span class="h1">ROLE OF HPV VACCINATION</span><span class="headingEndMark"> — </span>A history of cervical dysplasia or genital warts is <strong>not</strong> a contraindication to vaccination. In fact, in patients without HIV and a history of human papillomavirus (HPV) disease, HPV vaccination has been shown to provide protection against future infection from HPV types not already acquired and has been associated with a lower rate of CIN recurrence [<a href="#rid19">19,20</a>]. Although this has not been formally demonstrated among patients with HIV, it is likely also true in this setting, particularly given that many patients with HIV have a high rate of HPV coinfection [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management", section on 'HPV vaccination in patients with CIN'</a>.)</p><p>HPV vaccination in patients with HIV without CIN is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Patients with HIV or immunocompromising conditions'</a>.)</p><p class="headingAnchor" id="H3575298548"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Presentation of cervical cancer in patients with HIV is similar to that of patients without HIV and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>In patients with HIV, however, cervical carcinoma tends to be more advanced at diagnosis, and patients are frequently more debilitated [<a href="#rid22">22,23</a>]. Metastases are common and may occur at unexpected sites [<a href="#rid23">23,24</a>]. Some patients with cervical cancer are diagnosed while hospitalized for other manifestations of AIDS. Since some symptoms of AIDS are similar to those of advanced cancer (eg, weight loss, fatigue, and lymphadenopathy), the presence of cervical cancer may be masked.</p><p class="headingAnchor" id="H6"><span class="h1">MANAGEMENT OF PREINVASIVE DISEASE</span><span class="headingEndMark"> — </span>The appropriate management of patients with HIV and CIN, including optimal therapy with excision or ablation, role of postablative treatment with topical agents, and timing and method of follow-up, is largely unknown. Close follow-up by a provider with experience in HIV-related cervical disease is essential.</p><p class="headingAnchor" id="H7"><span class="h2">CIN 1</span><span class="headingEndMark"> — </span>In general, management (with observation or treatment [ie, excision or ablation]) of patients with CIN 1 and HIV is the same as patients without HIV infection and depends on the preceding cytology result (eg, low-grade squamous intraepithelial lesion [LSIL], high-grade squamous intraepithelial lesion [HSIL]) and age of the patient. We follow the American Society for Colposcopy and Cervical Pathology (ASCCP) consensus guidelines for the management of patients without HIV. This is described in detail separately. (See  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management", section on 'Management of patients ≥25 years'</a> and  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management", section on 'Management of patients &lt;25 years'</a>.)</p><p>CIN 1 is a low-grade lesion with at least one-third of patients with HIV showing <strong>regression</strong> [<a href="#rid17">17,25</a>]. Antiretroviral therapy (ART) is associated with increased rates of regression and decreased rates of recurrence in patients with HIV [<a href="#rid26">26,27</a>]. This is discussed in more detail below. (See <a class="local">'Antiretroviral therapy'</a> below.)</p><p>The risk of <strong>progression</strong> in patients with HIV is less clear. In two prospective studies including patients with HIV and CIN 1, progression occurred in 4 to 7 percent of patients [<a href="#rid28">28,29</a>]; other studies have reported higher rates [<a href="#rid26">26,30-32</a>], and progression can occur rapidly [<a href="#rid33">33</a>]. However, given this uncertainty and lack of data to define patient subgroups at higher or lower risk of progression, it is reasonable to follow the ASCCP guidelines for patients without HIV infection.</p><p class="headingAnchor" id="H23997166"><span class="h2">CIN 2,3</span></p><p class="headingAnchor" id="H8"><span class="h3">Excision or ablation</span><span class="headingEndMark"> — </span>In general, management of CIN 2,3 is the same for patients with and without HIV infection; when treatment is performed (ie, all CIN 3 lesions, most CIN 2 lesions), excision with either loop electrosurgical excision procedure (LEEP; also called large loop excision of the transformation zone) or cold knife conization is performed; excision has largely replaced the practice of ablation. Hysterectomy is occasionally performed instead of excision or ablation (eg, patient preference, additional gynecologic pathology such as symptomatic uterine fibroids) but is unacceptable as a primary treatment for CIN in most instances. The choice between excision and ablation is discussed in detail elsewhere and is the same in patients with HIV as in patients without HIV. (See  <a class="medical medical_review" href="/d/html/89208.html" rel="external">"Cervical intraepithelial neoplasia: Choosing excision versus ablation, and prognosis and follow-up after treatment"</a>.)</p><p>While success rates for these approaches in patients without HIV is over 90 percent [<a href="#rid34">34</a>], success rates are lower in patients with HIV. Persistence and recurrence of CIN after treatment have been reported in approximately 20 to 60 percent of patients with HIV [<a href="#rid35">35-40</a>]; recurrence rates also may be higher in patients undergoing cryotherapy compared with excision. Thus, for most patients with HIV, we suggest excision over ablation.</p><p>In a randomized trial comparing cryotherapy with LEEP for treatment of CIN 2,3 in 400 patients with HIV in Kenya, cryotherapy resulted in a higher rate of recurrence over two years (30 versus 19 percent, relative risk 1.7, 95% CI 1.1-2.7) [<a href="#rid40">40</a>]. Adverse events occurred in 20 percent of patients in the cryotherapy group (45 events, including change in pathology and death due to other causes) and in 15 percent of the LEEP group (38 events, including change in pathology and unrelated gynecologic complications). In a secondary analysis of this trial, clearance of high-risk HPV subtypes was higher in the LEEP compared with cryotherapy group (hazard ratio 1.4, 95% CI 1-1.9) during the 24-month study period [<a href="#rid41">41</a>].</p><p>Factors contributing to poorer treatment outcomes in patients with HIV include:</p><p class="bulletIndent1"><span class="glyph">●</span>Incomplete excision or ablation of CIN – In two studies of LEEP, CIN was found at the margins in all (11 of 11) tissue specimens of patients with HIV but in only 32 percent (86 of 265) of tissue specimens from patients without HIV [<a href="#rid42">42,43</a>]. It is not known why positive margins occurred more often among patients with HIV. In remaining at the margins, recurrence was more likely in patients with HIV compared with patients without HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression – In two reports, recurrence in patients with HIV was more common in patients with a CD4 count below 500/microL (45 versus 18 percent and 61 versus 20 percent) [<a href="#rid36">36,37</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Role of medical therapy</span><span class="headingEndMark"> — </span>Because results of standard excisional therapy are better in patients without versus with HIV, use of primary or adjuvant medical therapy to improve treatment outcomes in patients with HIV have been investigated. While little or no effect has been seen with oral <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">beta-carotene</a> [<a href="#rid44">44,45</a>], <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid46">46</a>], or systemic or intralesional interferon [<a href="#rid47">47,48</a>], other agents may have some benefits and are described here.</p><p class="headingAnchor" id="H10"><span class="h4">Topical fluorouracil</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) may be used as adjunctive therapy to excision/ablation procedures for CIN 2,3 [<a href="#rid49">49,50</a>], but we do not routinely use this in our practice. While there may be a reduction in the recurrence risk of CIN associated with the use of 5-FU, toxicity (eg, moderate-to-severe inflammation of the vulva and vagina) often limits its use.</p><p>The value of topical FU in patients with HIV was illustrated in a phase III trial supported by the AIDS Clinical Trials Group (ACTG 200) [<a href="#rid49">49</a>]. In this trial including 101 patients with HIV and previously treated CIN 2 or CIN 3, patients receiving six months of prophylaxis with FU (topical application of 2 g of 5% cream biweekly) compared with no treatment had reduced recurrence rates of any CIN (28 versus 47 percent) and high-grade lesions (8 versus 31 percent) on cervical cytology and colposcopy during the 18-month follow-up period. Patients in the FU-treatment group were more likely to experience at least one adverse effect (eg, abnormal bleeding, irritation, discharge) compared with the no-treatment group (32 versus 20 percent, respectively). A subsequent randomized trial including patients without HIV and histologically proven CIN 2,3 treated with 5-FU prior to their excisional procedure showed adverse events, though mild, occurred in the majority of patients (&gt;70 percent) [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H11"><span class="h4">Antiretroviral therapy</span><span class="headingEndMark"> — </span>ART is associated with improvement in CD4 counts and reductions in HIV viral load; improvements in these measures are also associated with a lower risk of CIN and cervical cancer [<a href="#rid11">11,13</a>]. This indirectly suggests that ART may reduce the incidence and recurrence of CIN in patients with HIV. ART also appears to be associated with regression of CIN [<a href="#rid27">27</a>].</p><p>Studies of the effect of ART on CIN are limited and conflicting because of small numbers of study participants and differences in study design [<a href="#rid17">17,26,27,52-57</a>]. The highest quality data come from a large, multicenter prospective cohort study by the Women's Interagency HIV Study Group which suggests that the benefit of ART is due, at least in part, to improvement in CD4 counts [<a href="#rid27">27</a>]. In this study including 312 patients with HIV and newly diagnosed CIN (the majority of whom [96 percent] had LSILs), rates of CIN regression were compared before and after initiating ART. Major findings from this study include:</p><p class="bulletIndent1"><span class="glyph">●</span>No incident CIN lesions regressed before the initiation of ART.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After initiation of ART, overall regression rate was 12.5 percent (95% CI 9.9-15.1) per year, with the incidence of regression increasing over time. Among the 312 patients, 45 percent had lesions that regressed to normal cytology, with a median time to regression of 2.7 years. By contrast, regression to normal cytology occurred in 16 of 27 (59 percent) patients without HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher rate of regression in patients with HIV taking ART was observed in patients with higher CD4 counts (336 versus 230 cells/microL) and low-grade incident CIN.</p><p></p><p>A subsequent prospective cohort study showed similar results [<a href="#rid58">58</a>]. In this study including 537 patients with HIV, there was a trend toward CIN regression in patients on ART compared with patients not taking ART, although this did not reach statistical significance. In addition, patients with CIN who did versus did not take ART were more likely to show clearance of HPV infection (high and low risk subtypes; hazard ratio 4.5, 95% CI 1.2-16.3); this effect was not seen in patients with normal or atypical squamous cells of undetermined significance cervical cytology.</p><p>Another study suggested that adherence to and effectiveness of ART regimens is associated with a reduced burden of HPV infection and squamous intraepithelial lesions (SILs). In this report, 286 patients with HIV were prescribed ART and followed prospectively. Those who used ART &gt;95 percent of the time and those who had effective suppression of HIV replication had significantly decreased prevalence of new HPV infections, as well as increased clearance of existing SILs [<a href="#rid59">59</a>].</p><p>The use of ART to improve the prognosis in patients with HIV and reduce the incidence of other neoplastic complications of AIDS is discussed separately. (See  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>In general, follow-up of CIN is more frequent in patients with HIV compared with patients without HIV (see  <a class="medical medical_review" href="/d/html/89208.html" rel="external">"Cervical intraepithelial neoplasia: Choosing excision versus ablation, and prognosis and follow-up after treatment", section on 'Follow-up after treatment'</a> and  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>); however, there is no consensus regarding the best approach and no formal guidelines exist.</p><p>In our practice, we recommend follow-up with both cervical cytology (with or without human papillomavirus [HPV] testing) and colposcopy (with liberal use of biopsy) at intervals of no longer than three months for an indefinite period. For patients for whom access to health care or follow-up testing is limited, the threshold for management may be lower (eg, hysterectomy rather than repeat cytology and colposcopy in a postmenopausal patient). (See <a class="local">'Patients with poorly controlled HIV'</a> below.)</p><p>Patients with HIV infection and CIN should be advised that recurrence is more frequent than in the general population and the risk of recurrence correlates with the degree of immunosuppression [<a href="#rid36">36-38,60</a>]. Recurrence rates are as high as 56 percent and up to 87 percent in severely immunocompromised (CD4 lymphocyte count &lt;200 cells/microL) patients [<a href="#rid1">1,38,61</a>]. Use of the various testing methods (ie, cytology, co-testing, routine colposcopy) is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3220.html" rel="external">"Screening for cervical cancer in patients with HIV infection and other immunocompromised states", section on 'Rationale and evidence for screening methods'</a>.)</p><p>Furthermore, cancer can develop rapidly in patients with HIV. A large study matching AIDS and cancer registries found that the average interval between diagnosis of CIN and development of invasive disease was considerably shorter in patients with HIV than in HIV-negative patients (3.2 versus 15.7 years, respectively) [<a href="#rid4">4</a>]. However, these data were largely obtained before widespread use of ART.</p><p>Long-term data on lower genital tract neoplasia in patients with HIV are limited. While it has been reported that multiple concurrent HPV-associated neoplasia may not be uncommon in patients with HIV, even in those whose disease is well controlled as measured by CD4 and viral loads [<a href="#rid62">62</a>], the same authors previously found that the overall outcomes were similar to those seen in patients not infected with HIV in the same population with 20-year follow-up [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT OF INVASIVE CANCER</span></p><p class="headingAnchor" id="H1396318596"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Standard therapy for invasive cervical cancer consists of surgery and/or chemoradiation therapy, irrespective of whether patients have HIV. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a> and  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a>.)</p><p>Surgical excision is most appropriate for early-stage disease, with adjuvant chemoradiation administered for those at intermediate or high risk of recurrence, as in patients without HIV. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Adjuvant therapy'</a>.)</p><p>Primary chemoradiation (without surgery) is used in patients with locally advanced disease, again, in similar fashion as in patients without HIV. (See  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Primary chemoradiation'</a>.)</p><p>Finally, chemotherapy alone is reserved for palliation.</p><p>Therapy of invasive cervical cancer in patients with HIV infection must take into consideration several additional factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV-associated cervical cancer are usually younger than patients without HIV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In most patients (26 of 28 in one report), invasive cervical cancer is the initial AIDS-defining diagnosis [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV and cervical cancer tend to be less immunosuppressed (as assessed by the CD4 count) than patients with HIV and other AIDS-defining illnesses [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The introduction of antiretroviral therapy (ART) did not decrease the incidence of invasive cervical cancer in the United States to the same degree as other malignancies associated with HIV infection (eg, Kaposi sarcoma, central nervous system non-Hodgkin lymphoma) [<a href="#rid66">66</a>]. This is because cervical cancer, unlike Kaposi sarcoma, was not a rare disease prior to the AIDS era and the vast majority of American patients with cervical cancer are not infected with HIV. Therefore, any reduction in risk of cervical neoplasia in patients with HIV had a minimal impact on the overall incidence of cervical cancer (see  <a class="medical medical_review" href="/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a>). However, ART may have a positive impact on prognosis [<a href="#rid67">67</a>]. (See <a class="local">'Antiretroviral therapy'</a> above.)</p><p></p><p>Based on these observations, aggressive therapy should be offered to most patients with HIV with cervical cancer. The patient should be informed that the prognosis in general is worse than in patients without HIV infection  (<a class="graphic graphic_table graphicRef64747" href="/d/graphic/64747.html" rel="external">table 1</a>), although this information is derived largely from patients not on ART, and that prognosis associated with concomitant antiviral therapy is not known. Some patients will be unwilling to tolerate the side effects associated with aggressive therapy if there is only a small chance of survival.</p><p class="headingAnchor" id="H1950817709"><span class="h2">Early-stage cervical cancer</span></p><p class="headingAnchor" id="H1503238382"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>As with patients without HIV, surgery is typically performed for patients with HIV and early-stage cervical cancer (ie, International Federation of Gynecology and Obstetrics [FIGO] stage IA, IB1, and IB2;  (<a class="graphic graphic_table graphicRef119447" href="/d/graphic/119447.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef139268" href="/d/graphic/139268.html" rel="external">table 3</a>)). The choice of procedure varies with the clinical setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Local excision by cold knife conization or loop electrosurgical excision procedure (LEEP) may be adequate for microinvasive lesions (&lt;3 mm depth of invasion) in patients who wish to maintain fertility. If future fertility is not an issue, simple hysterectomy is preferred. (See  <a class="medical medical_review" href="/d/html/3255.html" rel="external">"Cervical intraepithelial neoplasia: Diagnostic excisional procedures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modified radical or radical hysterectomy is appropriate for grossly visible tumors that are confined to the cervix (up to and including stage IB2).</p><p></p><p>This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Type of surgery'</a>.)</p><p>Advantages of surgery over radiation in such patients include preservation of ovarian function and decreased rates of sexual dysfunction (see  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Adverse effects'</a>). Although there is an increase in early morbidity with surgery (eg, anesthesia, blood loss, infection), overall morbidity from elective gynecology surgery does not appear to be increased in otherwise asymptomatic patients with HIV [<a href="#rid68">68</a>].</p><p>The addition of postoperative chemoradiotherapy should be considered for patients at increased risk of recurrent or persistent disease. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Indications'</a>.)</p><p class="headingAnchor" id="H3757374695"><span class="h2">Locally advanced cervical cancer</span></p><p class="headingAnchor" id="H17"><span class="h3">Chemoradiation</span><span class="headingEndMark"> — </span>Chemoradiation with curative intent is the preferred approach in locally advanced cervical cancer, irrespective of whether patients have HIV. (See  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Radiation therapy'</a>.)</p><p>The major advantage of a nonsurgical approach compared with surgical therapy for cervical cancer is less immediate morbidity.</p><p>However, pelvic chemoradiation in patients with HIV is not without adverse effects. Recovery from myelosuppression in immunosuppressed patients is, in general, typically slower than in immunocompetent patients, and as such, it may be slower in patients with versus without HIV. Depending on its severity, temporary cessation of therapy may be required. It is not known if pelvic chemoradiation therapy can potentiate the immunosuppressive effects of HIV infection.</p><p>Radiation proctitis is a potential complication of pelvic radiation that may be exacerbated by concomitant chemotherapy. It is usually treated symptomatically and, if available, topical butyrate enemas may accelerate healing [<a href="#rid69">69</a>]. If this is ineffective, radiation and chemotherapy should be withheld until the diarrhea resolves. (See  <a class="medical medical_review" href="/d/html/7058.html" rel="external">"Radiation proctitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p>The diarrhea must be distinguished from other forms of diarrhea associated with HIV infection (see  <a class="medical medical_review" href="/d/html/3728.html" rel="external">"Evaluation of the patient with HIV and diarrhea"</a>). Late complications of pelvic chemoradiotherapy, such as bowel obstruction and bowel and bladder fistulas, are uncommon.</p><p class="headingAnchor" id="H2020428959"><span class="h2">Metastatic cervical cancer</span></p><p class="headingAnchor" id="H18"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Chemotherapy alone can provide palliative benefit for patients with cervical cancer. The combination of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, and <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> has been shown to improve survival in patients with advanced or metastatic cervical cancer, and is considered the standard regimen for patients, irrespective of HIV infection [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer"</a>.)</p><p>There are limited data concerning the efficacy of chemotherapy in advanced cervical cancer in patients with HIV; a significant tumor response appears to be rare [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1631669122"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3380039422"><span class="h2">Patients with poorly controlled HIV</span><span class="headingEndMark"> — </span>For patients in whom HIV is poorly controlled (ie, high viral loads), who are unable to adhere to antiretroviral therapy (ART), have persistently low CD4 counts, or limited access to health care, the threshold for management of CIN may be lower and shorter follow-up intervals may be used. However, there is no standard management, largely because of the variability in presentation of these patients. In addition, priority is often given to optimizing the HIV infection (eg, restarting ART) and management of other acute conditions related to HIV, rather than treating CIN.</p><p class="headingAnchor" id="H2856920954"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117738.html" rel="external">"Society guideline links: Cervical cancer screening, prevention, and management"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical importance</strong> – Patients with HIV infection have higher rates of preinvasive (ie, cervical intraepithelial neoplasia [CIN]) and invasive cervical neoplasia compared with patients without HIV infection. Patients with HIV and cervical cancer are also at a higher risk for overall mortality than patients without HIV and cervical cancer. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and prevention</strong> – Infection with human papillomavirus (HPV) and the degree of immunosuppression (eg, CD4 count &lt;200 cells/microL) are thought to be key factors for both the occurrence and severity of cervical disease. A history of CIN or genital warts is <strong>not</strong> a contraindication to HPV vaccination. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Role of HPV vaccination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of antiretroviral therapy</strong> – Use of antiretroviral therapy in patients with HIV is associated with a lower risk of CIN and cervical cancer. (See <a class="local">'Antiretroviral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preinvasive disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – In general, management of patients with preinvasive disease (ie, CIN 1, 2, or 3) and HIV is the same as patients without HIV infection and we follow the American Society for Colposcopy and Cervical Pathology (ASCCP) consensus guidelines for the management of patients without HIV. (See  <a class="medical medical_review" href="/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CIN 1 or CIN 2, either excision or observation is performed, depending on the preceding cytology result (eg, low-grade squamous intraepithelial lesion [LSIL], high-grade squamous intraepithelial lesion [HSIL]) and the age of the patient. (See <a class="local">'CIN 1'</a> above and <a class="local">'CIN 2,3'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CIN 3, treatment is indicated. (See <a class="local">'CIN 2,3'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>When treatment is performed for CIN 1, 2, or 3, we perform excision rather than cryoablation. Excision is typically performed by loop electrosurgical excision procedure (LEEP). (See <a class="local">'Excision or ablation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Follow-up</strong> – Patients with HIV should be counseled that recurrence is more frequent than in the general population. As a result, in our practice, we monitor with both cervical cytology (with or without HPV testing) and colposcopy (with liberal use of biopsy) at intervals of no longer than three months for an indefinite period. (See <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Standard therapy for invasive cervical cancer consists of surgery and/or chemoradiation therapy, irrespective of whether patients have HIV (see  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a> and  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with early-stage disease, we perform surgical excision. For such patients with intermediate or high risk of recurrence, adjuvant chemoradiation is administered. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Adjuvant therapy'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with locally advanced disease, primary chemoradiation (without surgery) is used. (See  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Primary chemoradiation'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with metastatic disease as well as those who are not candidates for a local treatment approach, we administer chemotherapy. (See  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with poorly controlled HIV</strong> – For patients in whom HIV is poorly controlled (ie, high viral loads), are unable to adhere to antiretroviral therapy (ART), or have persistently low CD4 counts, the threshold for management of CIN may be lower and shorter follow-up intervals may be used. Priority is often given to optimizing the HIV infection (eg, restarting ART) and management of other acute conditions related to HIV. (See <a class="local">'Patients with poorly controlled HIV'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.</a></li><li><a class="nounderline abstract_t">Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190:1413.</a></li><li><a class="nounderline abstract_t">Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.</a></li><li><a class="nounderline abstract_t">Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.</a></li><li><a class="nounderline abstract_t">Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.</a></li><li><a class="nounderline abstract_t">Franceschi S, Dal Maso L, Arniani S, et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998; 78:966.</a></li><li><a class="nounderline abstract_t">Serraino D, Carrieri P, Pradier C, et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999; 82:334.</a></li><li><a class="nounderline abstract_t">Serraino D, Dal Maso L, La Vecchia C, Franceschi S. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002; 16:781.</a></li><li><a class="nounderline abstract_t">Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.</a></li><li><a class="nounderline abstract_t">Rositch AF, Levinson K, Suneja G, et al. Epidemiology of Cervical Adenocarcinoma and Squamous Cell Carcinoma Among Women Living With Human Immunodeficiency Virus Compared With the General Population in the United States. Clin Infect Dis 2022; 74:814.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226.</a></li><li><a class="nounderline abstract_t">Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008; 111:1380.</a></li><li><a class="nounderline abstract_t">Ahdieh L, Muñoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148.</a></li><li><a class="nounderline abstract_t">Theiler RN, Farr SL, Karon JM, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010; 115:1150.</a></li><li><a class="nounderline abstract_t">Maiman M, Tarricone N, Vieira J, et al. Colposcopic evaluation of human immunodeficiency virus-seropositive women. Obstet Gynecol 1991; 78:84.</a></li><li><a class="nounderline abstract_t">Schäfer A, Friedmann W, Mielke M, et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164:593.</a></li><li><a class="nounderline abstract_t">Delmas MC, Larsen C, van Benthem B, et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women. AIDS 2000; 14:1775.</a></li><li><a class="nounderline abstract_t">Leitao MM Jr, White P, Cracchiolo B. Cervical cancer in patients infected with the human immunodeficiency virus. Cancer 2008; 112:2683.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626.</a></li><li><a class="nounderline abstract_t">Lichter K, Krause D, Xu J, et al. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet Gynecol 2020; 135:1070.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24 Suppl 3:S3/140.</a></li><li><a class="nounderline abstract_t">Maiman M, Fruchter RG, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993; 71:402.</a></li><li><a class="nounderline abstract_t">Schwartz LB, Carcangiu ML, Bradham L, Schwartz PE. Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol 1991; 41:255.</a></li><li><a class="nounderline abstract_t">Singh GS, Aikins JK, Deger R, et al. Metastatic cervical cancer and pelvic inflammatory disease in an AIDS patient. Gynecol Oncol 1994; 54:372.</a></li><li><a class="nounderline abstract_t">Belafsky P, Clark RA, Kissinger P, Torres J. Natural history of low-grade squamous intraepithelial lesions in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:511.</a></li><li><a class="nounderline abstract_t">Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:538.</a></li><li><a class="nounderline abstract_t">Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070.</a></li><li><a class="nounderline abstract_t">Massad LS, Evans CT, Minkoff H, et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet Gynecol 2004; 104:1077.</a></li><li><a class="nounderline abstract_t">Del Mistro A, Bertorelle R, Franzetti M, et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004; 38:737.</a></li><li><a class="nounderline abstract_t">Robinson WR, Luck MB, Kendall MA, Darragh TM. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial. Am J Obstet Gynecol 2003; 188:896.</a></li><li><a class="nounderline abstract_t">Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92:727.</a></li><li><a class="nounderline abstract_t">Massad LS, Schneider M, Watts H, et al. Correlating Papanicolaou Smear, Colposcopic Impression, and Biopsy: Results from the Women's Interagency HIV Study. J Low Genit Tract Dis 2001; 5:212.</a></li><li><a class="nounderline abstract_t">Holcomb K, Maiman M, Dimaio T, Gates J. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. Obstet Gynecol 1998; 91:848.</a></li><li><a class="nounderline abstract_t">Burghardt E, Holzer E. Treatment of carcinoma in situ: evaluation of 1609 cases. Obstet Gynecol 1980; 55:539.</a></li><li><a class="nounderline abstract_t">Heard I, Bergeron C, Jeannel D, et al. Papanicolaou smears in human immunodeficiency virus-seropositive women during follow-up. Obstet Gynecol 1995; 86:749.</a></li><li><a class="nounderline abstract_t">Maiman M, Fruchter RG, Serur E, et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 1993; 82:170.</a></li><li><a class="nounderline abstract_t">Wright TC Jr, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol 1994; 55:253.</a></li><li><a class="nounderline abstract_t">Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87:338.</a></li><li><a class="nounderline abstract_t">Reimers LL, Sotardi S, Daniel D, et al. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol 2010; 119:92.</a></li><li><a class="nounderline abstract_t">Greene SA, De Vuyst H, John-Stewart GC, et al. Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial. JAMA 2019; 322:1570.</a></li><li><a class="nounderline abstract_t">Chung MH, De Vuyst H, Greene SA, et al. Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive Women: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2021; 7:1514.</a></li><li><a class="nounderline abstract_t">Robinson WR, Tirpack JS. The predictive value of LEEP specimens with involved margins for residual dysplasia. Int J Gynecol Cancer 1996; 6:140.</a></li><li><a class="nounderline abstract_t">Robinson WR, Lund ED, Adams J. The predictive value of LEEP specimen margin status for residual/recurrent cervical intraepithelial neoplasia. Int J Gynecol Oncol 1998; 8:109.</a></li><li><a class="nounderline abstract_t">Mackerras D, Irwig L, Simpson JM, et al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 1999; 79:1448.</a></li><li><a class="nounderline abstract_t">Romney SL, Ho GY, Palan PR, et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 1997; 65:483.</a></li><li><a class="nounderline abstract_t">Robinson WR, Andersen J, Darragh TM, et al. Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol 2002; 99:777.</a></li><li><a class="nounderline abstract_t">Frost L, Skajaa K, Hvidman LE, et al. No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1990; 97:626.</a></li><li><a class="nounderline abstract_t">Yliskoski M, Syrjänen K, Syrjänen S, et al. Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecol Oncol 1991; 43:55.</a></li><li><a class="nounderline abstract_t">Maiman M, Watts DH, Andersen J, et al. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet Gynecol 1999; 94:954.</a></li><li><a class="nounderline abstract_t">Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstet Gynecol Clin North Am 1987; 14:537.</a></li><li><a class="nounderline abstract_t">Fonseca BO, Possati-Resende JC, Salcedo MP, et al. Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix: A Randomized Controlled Trial. Obstet Gynecol 2021; 137:1043.</a></li><li><a class="nounderline abstract_t">Heard I, Schmitz V, Costagliola D, et al. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12:1459.</a></li><li><a class="nounderline abstract_t">Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16:1799.</a></li><li><a class="nounderline abstract_t">Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15:2157.</a></li><li><a class="nounderline abstract_t">Orlando G, Fasolo MM, Schiavini M, et al. Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients. AIDS 1999; 13:424.</a></li><li><a class="nounderline abstract_t">Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547.</a></li><li><a class="nounderline abstract_t">Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:128.</a></li><li><a class="nounderline abstract_t">Paramsothy P, Jamieson DJ, Heilig CM, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009; 113:26.</a></li><li><a class="nounderline abstract_t">Gravitt PE, Kirk GD. Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease. J Infect Dis 2010; 201:650.</a></li><li><a class="nounderline abstract_t">Gilles C, Manigart Y, Konopnicki D, et al. Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status. Gynecol Oncol 2005; 96:112.</a></li><li><a class="nounderline abstract_t">Heard I, Potard V, Foulot H, et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 2005; 39:412.</a></li><li><a class="nounderline abstract_t">Davis K, Rogg K, Robinson WR. The Incidence and Management of Human Papilloma Virus-Associated Malignancies in Immunocompetent Human Immunodeficiency Virus-Infected Women. Gynecol Oncol 2019.</a></li><li><a class="nounderline abstract_t">Robinson WR. Long-Term Follow-Up of HIV-Infected Women with Cervical Dysplasia. AIDS Patient Care STDS 2015; 29:517.</a></li><li><a class="nounderline abstract_t">Maiman M, Fruchter RG, Clark M, et al. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76.</a></li><li><a class="nounderline abstract_t">Klevens RM, Fleming PL, Mays MA, Frey R. Characteristics of women with AIDS and invasive cervical cancer. Obstet Gynecol 1996; 88:269.</a></li><li><a class="nounderline abstract_t">International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823.</a></li><li><a class="nounderline abstract_t">Robinson WR, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002; 16:61.</a></li><li><a class="nounderline abstract_t">Devito JR, Robinson WR. Gynecological surgical outcomes among asymptomatic human immunodeficiency virus-infected women and uninfected control subjects. J La State Med Soc 1995; 147:109.</a></li><li><a class="nounderline abstract_t">Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000; 356:1232.</a></li><li><a class="nounderline abstract_t">Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017; 390:1654.</a></li></ol></div><div id="topicVersionRevision">Topic 3245 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090399" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15378433" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697063" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence of cervical squamous intraepithelial lesions in HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10995805" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15770006" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764592" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10399949" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk of invasive cervical cancer among women with, or at risk for, HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964535" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Invasive cervical cancer as an AIDS-defining illness in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617273" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143885" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of Cervical Adenocarcinoma and Squamous Cell Carcinoma Among Women Living With Human Immunodeficiency Virus Compared With the General Population in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037100" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515522" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10905527" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20502284" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1675456" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Colposcopic evaluation of human immunodeficiency virus-seropositive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992708" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10985315" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18438877" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cervical cancer in patients infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20508593" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282601" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950001" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chapter 16: HPV vaccines in immunocompromised women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093678" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Human immunodeficiency virus infection and invasive cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869105" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8088616" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metastatic cervical cancer and pelvic inflammatory disease in an AIDS patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605598" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Natural history of low-grade squamous intraepithelial lesions in women infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11262450" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265968" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516404" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14986260" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712082" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764690" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Natural history of cervical squamous intraepithelial lesions: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050978" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Correlating Papanicolaou Smear, Colposcopic Impression, and Biopsy: Results from the Women's Interagency HIV Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572187" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7366911" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment of carcinoma in situ: evaluation of 1609 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566842" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Papanicolaou smears in human immunodeficiency virus-seropositive women during follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8101644" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7959293" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598951" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605046" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31638680" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34351377" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive Women: A Secondary Analysis of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The predictive value of LEEP specimens with involved margins for residual dysplasia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The predictive value of LEEP specimen margin status for residual/recurrent cervical intraepithelial neoplasia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10188889" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9190980" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978287" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2167727" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1660011" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10576182" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829084" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Anogenital papillomavirus infection and neoplasia in immunodeficient women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33957649" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727566" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12218392" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684935" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199237" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11494160" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12825181" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104356" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105079" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589589" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Management and outcome of cervical intraepithelial neoplasia lesions: a study of matched cases according to HIV status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010162" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Incidence and Management of Human Papilloma Virus-Associated Malignancies in Immunocompetent Human Immunodeficiency Virus-Infected Women</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26430720" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-Term Follow-Up of HIV-Infected Women with Cervical Dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8990442" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cervical cancer as an AIDS-defining illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8692514" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Characteristics of women with AIDS and invasive cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078759" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874637" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722403" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Gynecological surgical outcomes among asymptomatic human immunodeficiency virus-infected women and uninfected control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11072942" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Topical butyrate for acute radiation proctitis: randomised, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28756902" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
